On day 22, the tumor volume was 564±56 mm3 for the vehicle group while the tumor volume was 285±36 mm3 for the PA-2-treated group (98.2% inhibition, p<0.01), indicating that PA-2 is highly effective in suppressing the growth of ER+ breast cancer in vivo. Here, ESR1 is linked to breast cancer.